Regeneron Pharmaceuticals (REGN) : The total money flow in Regeneron Pharmaceuticals (REGN) was negative ($2.42 million), showing the domination of sellers in the Wednesday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $77.73 million. Transactions on upticks were comparatively lower at $75.31 million. The uptick to downtick ratio was 0.97. The total block trades on downticks were valued at $0 million. The money flow during block trades was negative ($0 million) when the stock traded with a gain of $31 cent. Regeneron Pharmaceuticals (REGN) was $421.76, an increase of 0.07% over the previous days close.
Shares of Regeneron Pharmaceuticals, Inc. rose by 3.09% in the last five trading days and 4.94% for the last 4 weeks. Regeneron Pharmaceuticals, Inc. is up 20.48% in the last 3-month period. Year-to-Date the stock performance stands at -22.8%.
Regeneron Pharmaceuticals (REGN) : The consensus on Regeneron Pharmaceuticals (REGN) based on 18 analyst recommendation on the company stock is 2.39, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Regeneron Pharmaceuticals (NASDAQ:REGN): stock was range-bound between the intraday low of $418.22 and the intraday high of $424.35 after having opened at $421.88 on Wednesdays session. The stock finally closed in the red at $421.88, a loss of -0.56%. The stock remained in the red for the whole trading day. The total traded volume was 779,435 shares. The stock failed to cross $424.35 in Wednesdays trading. The stocks closing price on Thursday was $421.45.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.